Immunotherapy

Papers
(The TQCC of Immunotherapy is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Immortal Time Bias in the Association Between Toxicity and Response for Immune Checkpoint Inhibitors: A Meta-Analysis93
Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings83
Atezolizumab in Advanced Hepatocellular Carcinoma: Good Things Come to Those Who Wait68
A Global Picture: Therapeutic Perspectives for COVID-1957
Systemic Immune–Inflammation Index Predicts Prognosis of Cancer Immunotherapy: Systemic Review and Meta-Analysis47
Real-world Study of Hepatic Artery Infusion Chemotherapy Combined With Anti-PD-1 Immunotherapy and Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma45
Immune Checkpoint Inhibitors and Chemotherapy in First-Line NSCLC: a Meta-Analysis35
TYK2 as a Therapeutic Target in the Treatment of Autoimmune and Inflammatory Diseases35
Tumor Cell-Based Vaccine: An Effective Strategy for Eradication of Cancer Cells33
Antimicrobial/Anticancer Peptides: Bioactive Molecules and Therapeutic Agents31
Cytokine Storm Modulation in COVID-19: A Proposed Role for Vitamin D and DPP-4 Inhibitor Combination Therapy (VIDPP-4i)31
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma31
Immunotherapy for Gastric Cancer: A 2021 Update27
Therapeutics to Tackle Omicron Outbreak27
Sutimlimab for Treatment of Cold Agglutinin Disease: Why, How And For Whom?27
Production of Hyperimmune Anti-SARS-CoV-2 Intravenous Immunoglobulin from Pooled COVID-19 Convalescent Plasma26
Peripheral Blood Eosinophil Count is Associated with Response to Chemoimmunotherapy in Metastatic Triple-Negative Breast Cancer25
Atherosclerosis: Immunopathogenesis and Strategies for Immunotherapy23
Blocking Egfr with Nimotuzumab: A Novel Strategy for Covid-19 Treatment22
Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer22
Targeted Allergen-Specific Immunotherapy within the Skin Improves Allergen Delivery to Induce Desensitization to Peanut21
Successful Use of Secukinumab in Two Melanoma Patients with Immune Checkpoint Inhibitor-Induced Inflammatory Arthropathy19
PD-L1 Expression as a Predictive Biomarker For Immune Checkpoint Inhibitors: Between a Dream And a Nightmare18
Phase I Studies of Peptide Vaccine Cocktails Derived from GPC3, WDRPUH and NEIL3 for Advanced Hepatocellular Carcinoma17
The Rationale for Targeting the JAK/STAT Pathway in Scleroderma-Associated Interstitial Lung Disease17
Chimeric Antigen Receptor Macrophage for Glioblastoma Immunotherapy: The Way Forward17
Emerging Advances in Cationic Liposomal Cancer Nanovaccines: Opportunities and Challenges17
Hematological Prognosticators in Metastatic Renal Cell Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis16
Overcoming Stromal Barriers to Immuno-Oncological Responses via Fibroblast Activation Protein-Targeted Therapy15
Integration of Immunotherapy into Adjuvant Therapy for Resected Non-Small-Cell Lung Cancer: ALCHEMIST Chemo-Io (ACCIO)15
Immune Checkpoint Inhibitors for Brain Metastases in Non-Small-Cell Lung Cancer: From Rationale to Clinical Application15
Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer15
Immunity to Glycan α-Gal and Possibilities for the Control of COVID-1915
Development of Hepatitis Triggered by SARS-CoV-2 Vaccination in Patient with Cancer During Immunotherapy: A Case Report15
Cellular Immunotherapy in Gastric Cancer: Adoptive Cell Therapy and Dendritic Cell-Based Vaccination14
Immune Checkpoint Inhibitors Use and Effects on Prognosis of COVID-19 Infection: A Systematic Review and Meta-Analysis14
Safety of Semi-Depot House Dust Mite Allergen Extract in Children and Adolescents with Allergic Rhinitis and Asthma14
Use of Immune Checkpoint Inhibitors in Cancer Patients with Pre-Existing Sarcoidosis13
Capillary-Leak Syndrome: An Unrecognized Early Immune Adverse Effect of Checkpoint-Inhibitors Treatment13
Efficacy of immunotherapy in KRAS -mutant non-small-cell lung cancer with comutations13
Anti-PD-1 Treatment-Induced Immediate Central Diabetes Insipidus: A Case Report13
Immunotherapy for Cholangiocarcinoma: a 2021 Update13
Pegcetacoplan Treatment for Geographic Atrophy Due to Age-Related Macular Degeneration: A Plain Language Summary of the FILLY Study12
Immunotherapy in Psoriasis12
Immunotherapy in Hematological Malignancies: Recent Advances and Open Questions12
Nivolumab-Induced Systemic Capillary Leak Syndrome as an Ultra Rare Life-Threatening Phenomenon of Late Toxicity and Intravenous Immunoglobulin Efficacy12
A Review of Secukinumab in Psoriasis Treatment12
The Safety and Efficacy of Immune-Checkpoint Inhibitors in Patients with Cancer and Pre-Existing Autoimmune Diseases11
Sargramostim and Immune Checkpoint Inhibitors: Combinatorial Therapeutic Studies in Metastatic Melanoma10
Front-Line Daratumumab-VTd Versus Standard-of-Care in ASCT-Eligible Multiple Myeloma: Matching-Adjusted Indirect Comparison10
Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review10
Immunology of Osteoporosis: Relevance of Inflammatory Targets for the Development of Novel Interventions10
Immune Checkpoint Inhibitors in Luminal Gastrointestinal Malignancies: Going Beyond MSI-H/dMMR, TMB and PD-L19
Overview of Subcutaneous Immunoglobulin 16.5% in Primary and Secondary Immunodeficiency Diseases9
Surrogate end Points for Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors9
Simultaneous Inhibition of PD-1 and LAG-3: the Future of Immunotherapy?9
Effectiveness of Durvalumab Consolidation in Stage III Non-Small-Cell Lung Cancer: Focus on Treatment Selection and Prognostic Factors9
Immune-Checkpoint Inhibitors in Renal Transplanted Patients Affected by Melanoma: A Systematic Review9
Chemotherapy or Chemo-Immunotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer: A Meta-Analysis9
Immune Cells and Signatures Characterize Tumor Microenvironment and Predict Outcome in Ovarian and Endometrial Cancers9
An Anti-CD6 Antibody for the Treatment of COVID-19 Patients with Cytokine-Release Syndrome: Report of Three Cases9
The Effect of Low-Dose Chemotherapy on the Tumor Microenvironment and its Antitumor Activity Combined with Anti-PD-1 Antibody9
Clinical Efficacy of Immune Checkpoint Inhibitors in Patients with Brain Metastases9
Immunoregulatory T cell Epitope Peptides for the Treatment of Allergic Disease8
Toxic Epidermal Necrolysis Associated with Chemoimmunotherapy For Lymphoma: Case Report and Literature Review8
Association of Circadian Timing of Initial Infusions of Immune Checkpoint Inhibitors with Survival in Advanced Melanoma8
Different Clinical Significance of Novel B7 Family Checkpoints VISTA and HHLA2 in Human Lung Adenocarcinoma8
Real-World Treatment Patterns and Outcomes in PD-L1-Positive Non-Small Cell Lung Cancer8
Pembrolizumab-Associated Erythema Nodosum in the Treatment of Metastatic Melanoma8
Clinical Efficacy and Safety of Efgartigimod for Treatment of Myasthenia Gravis8
Therapeutic Cancer Vaccine Therapy for Acute Myeloid Leukemia8
Determinants of Treatment for First-Line Immune-Based Combinations in Metastatic Renal Cell Carcinoma: a Critical Overview of Recent Evidence8
Immunotherapy Versus Standard Chemotherapy For Treatment of Extensive-Stage Small-Cell Lung Cancer: A Systematic Review8
Comparing Abrocitinib and Dupilumab in the Treatment of Atopic Dermatitis: A Plain Language Summary8
The Mrna Covid-19 Vaccine In Patients with Cancer Receiving Checkpoint Inhibitor Therapy: What we Know And What We Don’T8
IL-13 Antagonists in the Treatment of Atopic Dermatitis7
Efficacy and Safety of Chimeric Antigen Receptor T Cell Immunotherapy in B-Cell Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis7
Treatment of EAE Mice with Treg, G-MDSC and IL-2: a New Insight into Cell Therapy for Multiple Sclerosis7
Acute Interstitial Nephritis and PR3-ANCA Following Reintroduction of Pembrolizumab: A Case Report7
Prognosticating Role of Serum Eosinophils on Immunotherapy Efficacy in Patients with Advanced Melanoma7
A New Perspective on The Potential Application of Ripk1 in the Treatment of Sepsis7
Hurdles for the Wide Implementation of Photoimmunotherapy7
Real-world Maintenance Therapy and Survival Outcomes For Pembrolizumab Plus Pemetrexed and Platinum for Non-Small-Cell Lung Cancer in USA7
The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice7
Hla Loss of Heterozygosity-Mediated Discordant Responses to Immune Checkpoint Blockade in Squamous Cell Lung Cancer with Renal Metastasis7
Chimeric Antigen Receptor T cells Immunotherapy: Challenges and Opportunities in Hematological Malignancies7
Combined Application of Bevacizumab and Pd-1 Blockade Displays Durable Treatment Effects by Increasing the Infiltration And Cytotoxic Function of Cd8 + T Cells in Lu7
Secondary Pneumothorax During Immunotherapy in two Patients with Metastatic Solid Tumors; a New Entity7
Managing Viral Hepatitis in Cancer Patients Under Immune Checkpoint Inhibitors: Should we Take the Risk?7
Body Composition and Inflammation Impact in Non-Small-Cell Lung Cancer Patients Treated by First-line Immunotherapy6
Patient Needs and Benefits of Sublingual Immunotherapy for Grass Pollen-Induced Allergic Rhinitis: An Observational Study6
Small-Cell Breast Carcinoma with Response to Atezolizumab: A Case Report6
Delayed Immune-Related Neutropenia with Hepatitis By Pembrolizumab6
Targeting the Tumor Microenvironment of Ewing Sarcoma6
Urothelial Carcinoma in The Era of Immune Checkpoint Inhibitors6
Tocilizumab in Grade 4 Hepatitis Secondary to Immune Checkpoint Inhibitor: A Case Report and Review of the Literature6
Volume Increase of Spleen in Melanoma Patients Undergoing Immune Checkpoint Blockade6
Plasmodium Falciparum -Infected Humanized Mice: A Viable Preclinical Tool6
GO-BEYOND: A Real-World Study of Persistence of Golimumab in Patients with Axial Spondyloarthritis and Rheumatoid Arthritis in Turkey6
Dendritic Cell-Based Immunotherapy: A Potential Player in Oral Cancer Therapeutics6
Etrasimod for the Treatment of Ulcerative Colitis6
Cost–Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Treatment in PD-L1-Positive Metastatic Triple-Negative Breast Cancer6
Secukinumab in the Treatment of Hidradenitis Suppurativa6
Subcutaneous Immunoglobulin Use in Immunoglobulin-Naive Patients with Primary Immunodeficiency: A Systematic Review6
Venous Thromboembolism Events in Patients with Advanced Cancer on Immune Checkpoint Inhibitors6
Evaluation of PD-L1 as a Biomarker for Immunotherapy for Hepatocellular Carcinoma: Systematic Review and Meta-Analysis6
Abscopal Effect of Radiation Therapy and Nivolumab in a Patient with Combined Small-Cell Lung Cancer: A Case Report6
Lichenoid Drug Eruption on the Lower Lip Caused by Anti-PD-1 Monoclonal Antibody: A Case Report and Literature Review6
Vanishing Bile Duct Syndrome Following Pembrolizumab Infusion: Case Report and Review of the Literature6
Upadacitinib for Moderate to Severe Atopic Dermatitis6
First-Line Treatment of Advanced/Metastatic Melanoma with Anti-PD-1 Antibodies: Multicenter Experience in Poland6
Harnessing Gene Fusion-Derived Neoantigens for ‘Cold’ Breast and Prostate Tumor Immunotherapy6
Lights and Shadows on the Role of Rhg-CSF in Cancer Patients During the COVID-19 Pandemic and Future Perspectives of Research6
Immune Checkpoint Inhibitor-Induced Myocarditis, Myositis, Myasthenia Gravis and Transaminitis: A Case Series and Review6
Barriers and Solutions to Improve Access for Chimeric Antigen Receptor Therapies6
Effectiveness of COVID-19 Vaccines Against Omicron Variant5
Potential Biomarkers and Resistance Mechanisms of Atezolizumab in a Patient with Lung Squamous Cell Carcinoma5
Long-Term Immune-Related Adverse Events after Discontinuation of Immunotherapy5
Unconventional Radiotherapy to Enhance Immunotherapy Efficacy in Bulky Tumors: A Case Report5
Antibody Therapy Against Antibiotic-Resistant Diarrheagenic Escherichia Coli : A Systematic Review5
Adherence to Subcutaneous Biological Therapies in Patients with Inflammatory Rheumatic Diseases and Inflammatory Bowel Disease: A Systematic Review5
Pembrolizumab-Induced Follicular Eruption and Response to Isotretinoin5
Mechanisms of Allergen Immunotherapy Supporting its Disease-Modifying Effect5
Herpes Zoster in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors5
Mirna Profiles Change During Grass Pollen Immunotherapy Irrespective of Clinical Outcome5
Clinical Outcomes of Immune Checkpoint Inhibitor Diabetes Mellitus at a Comprehensive Cancer Center5
Systemic IgG Exposure and Safety in Patients with Primary Immunodeficiency: A Randomized Crossover Study Comparing a Novel Investigational Wearable Infusor Versus the Crono Pump5
A Case of Successful Pembrolizumab Rechallenge in a Patient with Non-Small-Cell Lung Cancer and Grade 3 Dermatomyositis5
Galectin-9 and PD-L1 Antibody Blockade Combination Therapy Inhibits Tumour Progression in Pancreatic Cancer5
BET Inhibitors: the Promise of a New Generation of Immunotherapy in Glioblastoma5
Treatment of Children with Primary Immunodeficiencies with a Subcutaneous Immunoglobulin 16.5% (Cutaquig ®  [Octanorm])5
Prognostic Value of Soluble Programmed Cell Death Ligand-1 in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis5
Safety and Effectiveness of the 300 IR Sublingual House Dust Mite Allergen Immunotherapy Tablet: 2-Year Interim Analysis of a Specified Drug-Use Survey5
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group)5
Use of Upadacitinib in the Treatment of Psoriatic Arthritis5
Immunotherapy in Atopic Dermatitis5
Clinical Course and Management of Pembrolizumab-Associated Isolated Adrenocorticotrophic Hormone Deficiency: A New Case and Literature Review5
Validation of a Drug-Based Score in Advanced Urothelial Carcinoma Treated with Pembrolizumab5
Immune Checkpoint Inhibitor-Induced Autoimmune Encephalitis in Metastatic Squamous Cell Lung Cancer5
A CD123-Specific Chimeric Antigen Receptor Augments Anti-Acute Myeloid Leukemia Activity of Vγ9Vδ2 T Cells5
Appropriate use of Antimicrobial Therapy For COVID-19 Co-Infection5
Safety and Efficacy of Mutant Neoantigen-Specific T-Cell Treatment Combined Anti-Pd-1 Therapy in Stage Iv Solid Tumors5
Rechallenge of Anti-PD-1/PD-L1 Antibody Showed a Good Response to Metastatic Breast Cancer: A Case Report5
Association of Immune-Related Adverse Events and Efficacy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis5
Mesenchymal Stem Cells Derived from Human Dental Follicle Modulate the Aberrant Immune Response in Atopic Dermatitis5
Under-Prescription of Allergen-Immunotherapy: Why is it Important to Prescribe it in Childhood Instead?5
Anti-PD-1 and Regorafenib Induce Severe Multisystem Adverse Events in Microsatellite Stability Metastatic Colorectal Cancer: A Case Report5
Pharmacokinetics and Safety of CT-P17 (40 mg/0.4 ml) Versus Reference Adalimumab: Randomized Study in Healthy Japanese Adults5
Takotsubo Syndrome in a Patient with Metastatic Renal Cell Carcinoma Treated with Pembrolizumab Plus Axitinib5
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis5
0.059604167938232